Synthis Therapeutics

Synthis Therapeutics is a biotech company in NYC developing the next generation of cell-targeted, TGFb therapies for both cancer and fibrotic diseases. TGFb is a clinically validated cancer pathway but systemic TGFb therapies cause tissue toxicity and have limited clinical efficacy. Using our internal expertise in antibody drug conjugates, TGFb and immunotherapies we developed our lead program, SYN101, which is a first in class, immune cell targeted TGFb therapy that selectively and safely blocks immune suppression to drive tumor clearance. As both a monotherapy and in combination with checkpoint blockade, SYN101 blocks tumor growth, restores immune function and establishes immunological memory, in multiple mouse tumor models in vivo. We are raising a $43M Series A for SYN101 development plus platform expansion into fibrotic diseases. SYN101 is differentiated from current clinical TGFb inhibitors, providing a safer and more efficacious alternative from systemic inhibitors.